8-Methoxypsoralen

CHF 166.00
In stock
CDX-M0156-G0055 gCHF 166.00
More Information
Product Details
Synonyms 8-MP; 8-MOP; 8-Methoxy-6,7-furanocoumarin; 9-Methoxyfuro[3,2-g][1]benzopyran-7-one; 5-Demethoxyisoimpinellin; Ammoidin; Methoxsalen; Xanthotoxin
Product Type Chemical
Properties
Formula C12H8O4
MW 216.19
CAS 298-81-7
Source/Host Chemicals Synthetic.
Purity Chemicals ≥95% (HPLC)
Appearance White to yellow powder.
Solubility Soluble in acetic acid or water (slightly).
Identity Determined by NMR.
Declaration Manufactured by Chemodex.
Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

InChi Key QXKHYNVANLEOEG-UHFFFAOYSA-N
Smiles COC1=C2OC=CC2=CC2=C1OC(=O)C=C2
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Keep cool and dry.
Protect from light and moisture.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF

Methoxsalen (8-Methoxypsoralen) is a potent tricyclic furocoumarin suicide inhibitor of CYP (cytochrome P-450). Has more potency than 5-MOP, 5-OH-P, DH-8-MOP and psoralen in inhibiting CYP2B1 (cytochrome P-450 2B1). Completely inhibits the metabolism of nicotine in vitro. Inhibits the metabolism of caffeine. Methoxsalen is a drug with photoactivating properties used to treat psoriasis, eczema, vitiligo and some cutaneous lymphomas in conjunction with exposing the skin to UVA light. Upon photoactivation, ultraviolet A (UVA) irradiation induces monoadducts and interstrand cross-links in DNA and therefore can be used to study DNA repair and recombination mechanisms.

Product References

(1) A. Lassus, et al.; Photodermatol. 1, 170 (1984) | (2) F.A. de Wolff, et al.; Clin. Pharmacokinet. 11, 62 (1986) | (3) G. Labbe, et al.; Biochem. Pharmacol. 36, 907 (1987) | (4) D.C. Mays, et al.; Clin. Pharmacol. Ther. 42, 621 (1987) | (5) G. Labbe, et al.; J. Pharmacol. Exp. Ther. 250, 1034 (1989) | (6) H.G. Jeong, et al.; BBRC 208, 1124 (1995) | (7) J.H. Gwang; Cancer Lett. 109, 115 (1996) | (8) M. Farhadi, et al.; Cell J. 15, 348 (2014) | (9) D. Bagdas, et al.; Neuropharmacol. 85, 67 (2014)

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.